再组合希鲁丁的铁酸化增加了对血栓素和抗血栓活性的亲和力
Alina Volkova1, Pavel Semenyuk2
1Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
Proteins
|October 20, 2023
概括
研究人员开发了新的希鲁丁衍生物,包括-希鲁丁,以改善抗凝剂活性. -希鲁丁表现出最高的亲和力和抗血栓疗效,显示出临床应用的前景.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 血凝素是血液凝固中的关键酶,也是抗凝剂的标.
- 希鲁丁是一种天然的血栓激素抑制剂,由于缺乏Tyr63硫化物的复合形式的活性降低,其临床使用受限.
- 开发有效的希鲁丁类似物对于推进抗凝固疗法至关重要.
研究的目的:
- 设计和评估具有增强血栓亲和力和抗凝活性的新型希鲁丁衍生物.
- 调查Tyr63和Gln65修改对希鲁丁与血栓的相互作用的影响.
- 为了确定有前途的候选人临床抗凝剂的发展.
主要方法:
- 希鲁丁衍生物的合成和测试:-Tyr63,Tyr63 ((carboxymethyl) Phe,Tyr63Glu,Gln65Glu,以及素糖化希鲁丁.
- 引导分子动力学模拟和雨采样,以评估对血栓的结合亲和力.
- 在人体血中进行体外抗血栓活性测定.
主要成果:
- 在所有测试的类似物中,-希鲁丁表现出对血栓的最高结合亲和力,超过了原生硫化希鲁丁.
- Lysine-succinylated hirudin 也显示出对血栓的有希望的亲和力.
- -希鲁丁在人体血测定中表现出优异的抗血栓活性.
结论:
- -希鲁丁是一种高效的希鲁丁类似物,具有较高的血栓亲和力和抗血栓活性.
- 改性希鲁丁,特别是-希鲁丁和化希鲁丁,具有作为临床抗凝剂的巨大潜力.
- 生产方法的进步使这些衍生品可用于治疗应用.
更多相关视频
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
513
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
723
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
723
01:26Receptor Tyrosine Kinases
13.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
192
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192